On July 8, 2025, the Department of Justice ("DOJ") and the U.S. Postal Service ("USPS") announced a Whistleblower Rewards Program that will provide financial incentives to individuals who report antitrust crimes and related...more
7/14/2025
/ Antitrust Provisions ,
Antitrust Violations ,
Competition ,
Criminal Convictions ,
Department of Justice (DOJ) ,
Penalties ,
Regulatory Reform ,
Reporting Requirements ,
Risk Management ,
USPS ,
Whistleblower Awards ,
Whistleblower Protection Policies ,
Whistleblowers
The Center for Medicare and Medicaid Innovation ("CMMI") is set to reshape value-based care. In the third of a three-part series highlighting this new direction, this summary is focused on CMMI's efforts regarding drugs,...more
6/13/2025
/ Centers for Medicare & Medicaid Services (CMS) ,
CMMI ,
Data Collection ,
Data Management ,
Digital Health ,
Drug Pricing ,
Health Insurance ,
Healthcare ,
Healthcare Reform ,
Life Sciences ,
Medicaid ,
Medical Devices ,
Medicare ,
Patient Access ,
Pharmaceutical Industry ,
Value-Based Care
Under a new U.S. Department of Justice ("DOJ") policy related to mergers and acquisitions ("M&A"), DOJ will decline to prosecute an acquiring company for misconduct by an acquired company where the acquiring company timely...more
The U.S. Department of Justice Antitrust Division ("DOJ") recently resolved a criminal case with Teva Pharmaceuticals and Glenmark Pharmaceuticals via deferred prosecution agreements ("DPAs"), which include a novel remedy for...more
9/5/2023
/ Anti-Competitive ,
Antitrust Violations ,
Bid Rigging ,
Competition ,
Corporate Counsel ,
Criminal Antitrust Litigation ,
Criminal Conspiracy ,
Criminal Investigations ,
Criminal Prosecution ,
Deferred Prosecution Agreements ,
Department of Justice (DOJ) ,
Divestiture ,
Enforcement Actions ,
Generic Drugs ,
Health Care Providers ,
Healthcare ,
Indictments ,
Life Sciences ,
Pharmaceutical Industry ,
Popular ,
Price-Fixing ,
Teva Pharmaceuticals
A Connecticut district court acquitted six defendants of criminal antitrust violations arising out of alleged employee no-poach agreements, marking the first dismissal of a U.S. Department of Justice, Antitrust Division's...more
The Senate Judiciary Committee is showing renewed Congressional interest in oversight of the pharmaceutical industry, with five bipartisan drug bills on the agenda for review and discussion on February 9, 2023....more
The United States Department of Agriculture ("USDA") published the Strengthening Organic Enforcement ("SOE") Final Rule to improve farm-to-market traceability, deter and detect instances of organic fraud, increase oversight,...more
A plea deal with a paving contractor follows the Department of Justice Antitrust Division's ("DOJ") threat to resurrect criminal enforcement of the Sherman Act § 2 prohibition on monopolization and attempted monopolization....more
The DOJ Antitrust Division recently announced new requirements for DOJ's Leniency Program, which allows the first individual or company to self-report its involvement in an antitrust conspiracy to avoid prosecution and lessen...more
Last week, the Patient Right to Know Drug Prices Act ("Act") became law. The Act requires pharmaceutical companies to disclose to antitrust agencies agreements between biologic and biosimilar companies that relate to the...more
10/19/2018
/ Antitrust Division ,
Disclosure Requirements ,
Federal Trade Commission (FTC) ,
Hatch-Waxman ,
Life Sciences ,
Manufacturers ,
Medicare Prescription Drug Improvement and Modernization Act (MMA) ,
Patents ,
Pharmaceutical Industry ,
Popular ,
Prescription Drugs
A federal district court has ordered a defendant in private antitrust litigation to divest a manufacturing plant following a competitor's merger challenge. Although the decision is certain to be appealed, it may embolden...more
The U.S. Department of Justice indicted Bumble Bee Foods CEO Christopher Lischewski on price-fixing charges. Lischewski is the first CEO to be charged for his role in the alleged U.S. conspiracy to fix the price of packaged...more
The Situation: The U.S. Department of Justice Antitrust Division ("DOJ") has adopted new terms in recent consent decrees that enhance DOJ's ability to enforce its settlements, most importantly by lowering the evidentiary...more
2/12/2018
/ Antitrust Division ,
Antitrust Investigations ,
Attorney's Fees ,
Burden of Proof ,
CFIUS ,
Consent Decrees ,
Corporate Counsel ,
Department of Justice (DOJ) ,
Enforcement Actions ,
Evidentiary Standards ,
Federal Trade Commission (FTC) ,
Fee-Shifting ,
Mergers